Enkasai Pharmaceuticals Completes 100 Million Yuan Series A Financing

Enkai Cell is a NK cell drug developer. The company focuses on the transformation and development of innovative cell drug technology based on NK cells, and is committed to providing more effective and safe precise immunotherapy methods for the majority of patients. The company’s core business is the development of NK cell drugs, which has formed a distinctive feature. The main development projects include four categories of twelve series of technologies and products. Recently, Nkesai Pharmaceuticals announced the completion of a series A financing of more than 100 million yuan. This round of financing was led by Huagai Capital, followed by Chinese Academy of Sciences Venture Capital, Gandao Fund, Chengyi Capital, Sirius Capital, and Qiao Jing Capital. The funds raised in this round will be used for the research and development of a series of NK cell drug product pipelines at various stages.

This article is reproduced from: https://www.itjuzi.com/investevent/13315719
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment